RBI receives FDA approval to proceed with Human Testing (IND 111446) for its AppliGel Polymer Drug Delivery System

Written by royerbio on Jun 6th, 2012 in News | Comments Off on RBI receives FDA approval to proceed with Human Testing (IND 111446) for its AppliGel Polymer Drug Delivery System

FREDERICK, Md.–(BUSINESS WIRE)–Royer Biomedical, Inc. (RBI) received FDA approval to proceed with Human Testing of AppliGel-G (Gentamicin) in management of Diabetic Foot Ulcers (DFU). AppliGel is a patented proprietary dissolvable non-immunogenic Polymer Drug Delivery System Platform. It has demonstrated efficacy in biofilm and infection eradication, without significant systemic API levels. “This represents an important milestone in the development of AppliGel”. […]

Continue Reading

Royer Biomedical, Inc. Awarded US Patent for its AppliGel Polymer Drug Delivery System

Written by royerbio on Dec 19th, 2011 in News | Comments Off on Royer Biomedical, Inc. Awarded US Patent for its AppliGel Polymer Drug Delivery System

FREDERICK, Md.–(BUSINESS WIRE)—Royer Biomedical Inc. (RBI) was awarded a US patent covering the core technologies of its proprietary AppliGel dissolvable non-immunogenic Polymer Drug Delivery System Platform. The US Patent and Trademark Office allowed 53 claims broadly covering composition of matter, methods, commercial kits, and formulations. AppliGel Drug Delivery System Platform received pre-IND pathway concurrence earlier this year. The Company is […]

Continue Reading